Motilium 10 mg Tablets

Motilium in the United States: start with the access status

Motilium 10 mg film-coated tablets contain domperidone. Domperidone is not FDA-approved for human use and is not currently a legally marketed human medicine in the United States. For that reason, our product listing must not be read as an ordinary US treatment option for nausea or vomiting. The relevant US pathway is FDA expanded access for a limited group of patients under an investigational new drug application, or IND, administered by an eligible physician.

FDA describes this pathway for patients aged 12 years or older with certain serious gastrointestinal motility disorders who have not responded to standard therapies. The listed conditions include gastroesophageal reflux disease with upper gastrointestinal symptoms, gastroparesis, and chronic constipation. Routine short-term nausea, motion sickness, or an isolated episode of vomiting does not by itself establish eligibility for this program.

The current expanded-access supply situation

Access depends on more than a physician deciding that domperidone may be useful. FDA reported that the supplier serving the previous expanded-access program stopped distributing domperidone after September 2025. A physician who identifies a new supplier may submit a new expanded-access IND for consideration. When that supplier distributes the investigational medicine from outside the United States, the physician-sponsor must also meet the applicable IND importation requirements.

This means that a previous domperidone prescription, an older IND, or the existence of tablets in our catalogue does not confirm that a patient currently has an authorized supply route. The physician overseeing the case must establish the current pathway and obtain FDA authorization before treatment. We cannot determine IND eligibility or replace the physician-sponsor's responsibilities through our checkout.

Product identity

The product we list is Motilium containing 10 mg of domperidone in a film-coated tablet for oral use. We do not list a liquid, orally disintegrating, injectable, or extended-release form under this product page. The available quantities are 10, 20, 30, 60, 90, 120, 180, 270, and 360 tablets. These are catalogue package quantities, not FDA-authorized course sizes.

Every quantity has the same strength and dosage form. A larger package does not establish a higher dose, a longer treatment period, or approval for repeated courses. Under expanded access, the physician's IND protocol and the supplied investigational product documentation control the dose, monitoring, duration, and quantity.

Why clinical review is essential

FDA associates domperidone with serious cardiac risks, including abnormal heart rhythms, cardiac arrest, and sudden death. Higher domperidone concentrations in the blood are associated with greater risk. The physician must therefore consider the patient's medical history, other medicines, electrolyte status, and the monitoring required by the IND protocol.

Particular attention is needed when another medicine can prolong the QT interval or raise domperidone concentrations through CYP3A4 inhibition. Examples can include certain azole antifungals, macrolide antibiotics, antiviral medicines, antidepressants, antipsychotics, and other drugs with cardiac electrophysiology effects. The exact products and doses matter, so a complete medication list must be reviewed rather than relying on a general drug-class comparison.

Fainting, a fast or irregular heartbeat, severe dizziness, chest discomfort, or a seizure can indicate a serious problem and require urgent medical attention. Pregnancy, breastfeeding, heart disease, impaired liver function, low potassium or magnesium, and a history of unexplained fainting also require individual assessment. FDA specifically warns against using domperidone to increase milk production because of serious cardiac risk and the lack of an approved US use.

No general US dosing schedule applies

There is no FDA-approved US dosing schedule for Motilium or domperidone. Directions used in another country for short-term nausea and vomiting must not be presented as the US expanded-access regimen. A qualifying patient must follow the dose, timing, monitoring plan, and stopping instructions specified by the physician responsible for the IND and the documentation for the actual investigational product supplied.

Do not infer a regimen from the 10 mg tablet strength or from the number of tablets in a package. Do not increase the dose, continue treatment longer, restart leftover tablets, or use another person's supply. Any change belongs within the physician-supervised IND process.

How standard therapies fit into the decision

Expanded access is considered only after comparable or satisfactory standard therapies have not worked or cannot be used. The relevant alternatives depend on the diagnosed motility disorder. For example, Reglan (metoclopramide) has an established US role in selected cases of diabetic gastroparesis, but it has its own neurologic risks and duration limits. Acid-suppressing treatment may be relevant to some reflux symptoms, while constipation may require a different treatment strategy. None of these options is interchangeable solely because symptoms overlap.

The treating physician must document why standard treatment is inadequate and why the potential benefit of investigational domperidone justifies its risks. Our catalogue and support team cannot make that clinical or regulatory determination.

Our ordering policy does not replace FDA authorization

Our checkout does not require a prescription document to be uploaded for this listing. That is only our administrative ordering policy. It does not make domperidone FDA-approved, legally marketed in the United States, or available outside the expanded-access rules. It also does not establish that a customer qualifies for an IND or that a particular shipment may lawfully serve as the investigational supply.

Before ordering for delivery to the United States, the patient and physician should confirm the current supplier, the IND authorization, the permitted importation route when relevant, the exact product, and the quantity authorized by the protocol. We can answer questions about our listing and checkout, but the physician-sponsor and FDA control the expanded-access process.

Receiving and storing the listed tablets

If tablets are supplied through an authorized pathway, compare the received package with the product and documentation approved for the IND. Check the active ingredient, 10 mg strength, film-coated tablet form, manufacturer, lot number, expiration date, seal, and package condition. A difference in appearance alone does not prove that the medicine is wrong, but a discrepancy in identity, strength, dosage form, labeling, or integrity must be resolved before use.

Store the tablets below 86°F in the original package, protected from light and moisture, unless the documentation accompanying the actual product gives more specific instructions. Keep them out of the reach of children and do not use damaged or expired tablets.

The practical decision for a US customer

Motilium is not a routine US antiemetic purchase. The first question is whether an eligible physician has determined that a serious gastrointestinal motility disorder may justify domperidone after standard therapies have failed. The next questions are whether a compliant supplier is available, whether FDA has authorized the IND, and whether the exact 10 mg tablet product and quantity match that protocol.

If those points have not been resolved, selecting a package from our catalogue is premature. Our lack of a prescription-upload requirement cannot substitute for the expanded-access process, cardiac-risk review, monitoring, or lawful supply arrangements.